A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder
Latest Information Update: 02 Feb 2021
At a glance
- Drugs Lemborexant (Primary) ; Flurazepam
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 01 Jan 2021 Results assessing potential of lemborexant for residual morning and next-day effects, including somnolence from 9 studies (E2006-A001-001 Part B, E2006-A001-002, E2006-A001-003, E2006-E044-106, E2006-A001-107, E2006-A001-108, E2006-G000-201, E2006-G000-303 & E2006-G000-304) published in the Postgraduate Medicine.
- 29 May 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 03 Feb 2015 New trial record